4-Methyl-3,6-dimethoxy-pyridazin | 89943-29-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Methyl-3,6-dimethoxy-pyridazin
• 英文别名: 3,6-dimethoxy-4-methyl-pyridazine；3,6-Dimethoxy-4-methyl-pyridazin；3,6-Dimethoxy-4-methylpyridazine
• CAS: 89943-29-3
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD09959871
• 分子量: 154.169
• InChiKey: FODLXNPPUWRDEJ-UHFFFAOYSA-N

物化性质

• 熔点：
  80-81 °C
• 沸点：
  307.7±37.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  44.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-甲基-3,6-二羟基哒嗪 在 甲醇 、 三氯氧磷 作用下， 生成 4-Methyl-3,6-dimethoxy-pyridazin
  参考文献：
  名称：

  杂环研究中的化学研究。4. Mitteilung。哒嗪类衍生物

  摘要：

  描述了许多3-和6-位取代的哒嗪和4-甲基哒嗪用于药理研究。某些3,6-二烷氧基-哒嗪具有良好的抗惊厥性质。3,6-二肼基哒嗪在其药理特性上类似于降血压药“ A presoline”和“ Nepresol”。3-氨基-6-氯哒嗪的磺基衍生物具有优异的抗菌作用。

  DOI：

  10.1002/hlca.19540370115

文献信息

• Substituted heteroarylamide oxazepinopyrimidone derivatives
  申请人：Sanofi-Aventis

  公开号：EP2085400A1

  公开（公告）日：2009-08-05

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R3 represents a 4-15 membered heterocyclic group, this group being optionally substituted; R4 represents a hydrogen atom or a C1-6 alkyl group; and n represents 0 to 3 and their therapeutic use.

  一种由式（I）表示的吡啶酮衍生物或其盐，或其溶剂或水合物： 其中： Y代表两个氢原子，一个硫原子，一个氧原子或一个C1-2烷基和一个氢原子； Z代表键，一个氧原子，一个氮原子，该氮原子被一个氢原子或C1-3烷基取代，一个硫原子，一个亚甲基，该亚甲基可选地被选自C1-6烷基，羟基，C1-6烷氧基，C1-2全氟烷基或氨基的一或两个基团取代； R1代表2、3或4-吡啶环或2、4或5-嘧啶环，该环可选地被C1-6烷基，C1-6烷氧基或卤素原子取代； R2代表氢原子，C1-6烷基或卤素原子； R3代表4-15成员的杂环基，该基团可选地被取代； R4代表氢原子或C1-6烷基； n代表0到3及其治疗用途。
• SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES
  申请人：FAYOL Aude

  公开号：US20090306088A1

  公开（公告）日：2009-12-10

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof are disclosed and claimed. Wherein m, n, o, Y, Z, R1, R2, R3, R4, R5 R6 and R7 are as described herein. Also disclosed are the salts of compounds of formula (I). The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明揭示和声明了由式(I)表示的吡啶酮衍生物，或其盐、溶剂或水合物。其中m、n、o、Y、Z、R1、R2、R3、R4、R5、R6和R7如本文所述。本发明还揭示了式(I)化合物的盐。本发明涉及一种药物，其包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• SUBSTITUTED HETEROARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES
  申请人：FAYOL Aude

  公开号：US20110015187A1

  公开（公告）日：2011-01-20

  The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y, Z, R1, R2, R3, R4, R5 and n are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

  本公开涉及一系列由式（I）或其盐，溶剂或水合物表示的嘧啶酮衍生物：其中：Y、Z、R1、R2、R3、R4、R5和n如本公开所定义。还公开了制备式（I）化合物的方法，其中间体以及它们在治疗各种疾病条件方面的用途。
• SUBSTITUTED HETEROARYLAMIDE OXAZEPINOPYRIMIDONE DERIVATIVES
  申请人：FAYOL Aude

  公开号：US20110015176A1

  公开（公告）日：2011-01-20

  The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: Y, Z, R1, R2, R3, R4 and n are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates therefor and their utility in treating a variety of disease conditions.

  本公开涉及一系列以式（I）表示的嘧啶酮衍生物或其盐、溶剂或水合物：其中：Y、Z、R1、R2、R3、R4和n如本公开所定义。同时还公开了制备式（I）化合物的方法、其中间体以及它们在治疗各种疾病状况中的用途。
• Ortho-directed lithiation in .pi.-deficient diazinyl heterocycles
  作者：Ronald J. Mattson、Charles P. Sloan

  DOI：10.1021/jo00297a085

  日期：1990.5